Skip to main content
Top
Published in: International Journal of Hematology 1/2015

01-07-2015 | Original Article

Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers

Authors: Sarah Farmer, Hanne Vestergaard, Stinus Hansen, Vikram Vinod Shanbhoque, Claudia Irene Stahlberg, Anne Pernille Hermann, Henrik Frederiksen

Published in: International Journal of Hematology | Issue 1/2015

Login to get access

Abstract

Primary myelofibrosis (MF) is a severe chronic myeloproliferative neoplasm, progressing towards a terminal stage with insufficient haematopoiesis and osteosclerotic manifestations. Whilst densitometry studies have showed MF patients to have elevated bone mineral density, data on bone geometry and micro-structure assessed with non-invasive methods are lacking. We measured areal bone mineral density (aBMD) using dual-energy X-ray absorptiometry (DXA). Bone geometry, volumetric BMD, and micro-architecture were measured using high-resolution peripheral quantitative computed tomography (HR-pQCT). We compared the structural parameters of bones by comparing 18 patients with MF and healthy controls matched for age, sex, and height. Blood was analysed for biochemical markers of bone turnover in patients with MF. There were no significant differences in measurements of bone geometry, volumetric bone mineral density, and micro-structure between MF patients and matched controls. Estimated bone stiffness and bone strength were similar between MF patients and controls. The level of pro-collagen type 1 N-terminal pro-peptide (P1NP) was significantly increased in MF, which may indicate extensive collagen synthesis, one of the major diagnostic criteria in MF. We conclude that bone mineral density, geometry, and micro-architecture in this cohort of MF patients are comparable with those in healthy individuals.
Appendix
Available only for authorised users
Literature
1.
go back to reference Swerdlow SHCE, Harris NL et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. France: IARC; 2008. Swerdlow SHCE, Harris NL et al. WHO classification of tumours of the haematopoietic and lymphoid tissues. France: IARC; 2008.
2.
go back to reference Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Current Hematol Malig Rep. 2009;4(1):33–40.CrossRef Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Current Hematol Malig Rep. 2009;4(1):33–40.CrossRef
3.
go back to reference Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.PubMed Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372–5.PubMed
4.
go back to reference Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRefPubMed Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRefPubMed
5.
go back to reference Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.CrossRefPubMed Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.CrossRefPubMed
7.
go back to reference Mellibovsky L, Marinoso ML, Cervantes F, Besses C, Nacher M, Nogues X, et al. Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis. Bone. 2004;34(2):330–5.CrossRefPubMed Mellibovsky L, Marinoso ML, Cervantes F, Besses C, Nacher M, Nogues X, et al. Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis. Bone. 2004;34(2):330–5.CrossRefPubMed
8.
go back to reference Diamond T, Smith A, Schnier R, Manoharan A. Syndrome of myelofibrosis and osteosclerosis: a series of case reports and review of the literature. Bone. 2002;30(3):498–501.CrossRefPubMed Diamond T, Smith A, Schnier R, Manoharan A. Syndrome of myelofibrosis and osteosclerosis: a series of case reports and review of the literature. Bone. 2002;30(3):498–501.CrossRefPubMed
9.
go back to reference Poulsen LW, Melsen F, Bendix K. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis. APMIS Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1998;106(4):495–9.CrossRefPubMed Poulsen LW, Melsen F, Bendix K. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis. APMIS Acta Pathologica, Microbiologica, et Immunologica Scandinavica. 1998;106(4):495–9.CrossRefPubMed
10.
go back to reference Guermazi A, de Kerviler E, Cazals-Hatem D, Zagdanski AM, Frija J. Imaging findings in patients with myelofibrosis. Eur Radiol. 1999;9(7):1366–75.CrossRefPubMed Guermazi A, de Kerviler E, Cazals-Hatem D, Zagdanski AM, Frija J. Imaging findings in patients with myelofibrosis. Eur Radiol. 1999;9(7):1366–75.CrossRefPubMed
11.
go back to reference Farmer S, Horvath-Puho E, Vestergaard H, Hermann AP, Frederiksen H. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol. 2013;163(5):603–10.CrossRefPubMed Farmer S, Horvath-Puho E, Vestergaard H, Hermann AP, Frederiksen H. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol. 2013;163(5):603–10.CrossRefPubMed
12.
go back to reference Consensus development conference. diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–50.CrossRef Consensus development conference. diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646–50.CrossRef
13.
go back to reference Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.PubMedCentralCrossRefPubMed Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312(7041):1254–9.PubMedCentralCrossRefPubMed
14.
go back to reference Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res Off J Am Soc Bone Miner Res. 2003;18(11):1947–54.CrossRef Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. J Bone Miner Res Off J Am Soc Bone Miner Res. 2003;18(11):1947–54.CrossRef
15.
go back to reference Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195–202.CrossRefPubMed Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34(1):195–202.CrossRefPubMed
16.
go back to reference Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90(12):6508–15.CrossRefPubMed Boutroy S, Bouxsein ML, Munoz F, Delmas PD. In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005;90(12):6508–15.CrossRefPubMed
17.
go back to reference Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420 (A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA).CrossRefPubMed Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420 (A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA).CrossRefPubMed
18.
19.
go back to reference Schmidt M, Pedersen L, Sorensen HT. The danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.CrossRefPubMed Schmidt M, Pedersen L, Sorensen HT. The danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–9.CrossRefPubMed
20.
go back to reference Hansen S, Shanbhogue V, Folkestad L, Nielsen MM, Brixen K. Bone microarchitecture and estimated strength in 499 adult danish women and men: a cross-sectional population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. Calcified tissue international. 2013;94:269.CrossRefPubMed Hansen S, Shanbhogue V, Folkestad L, Nielsen MM, Brixen K. Bone microarchitecture and estimated strength in 499 adult danish women and men: a cross-sectional population-based high-resolution peripheral quantitative computed tomographic study on peak bone structure. Calcified tissue international. 2013;94:269.CrossRefPubMed
21.
go back to reference Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Rev Cancer. 2007;7(9):673–83.CrossRef Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Rev Cancer. 2007;7(9):673–83.CrossRef
22.
go back to reference Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):392–7.CrossRef Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(4):392–7.CrossRef
23.
go back to reference Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.CrossRefPubMed Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703–8.CrossRefPubMed
24.
go back to reference Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S. Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(5):983–93. Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S. Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(5):983–93.
25.
go back to reference Nishiyama KK, Macdonald HM, Buie HR, Hanley DA, Boyd SK. Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(4):882–90. Nishiyama KK, Macdonald HM, Buie HR, Hanley DA, Boyd SK. Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(4):882–90.
26.
go back to reference Pistoia W, van Rietbergen B, Lochmuller EM, Lill CA, Eckstein F, Ruegsegger P. Image-based micro-finite-element modeling for improved distal radius strength diagnosis: moving from bench to bedside. J Clin Densitom Off J Int Soc Clin Densitom. 2004;7(2):153–60.CrossRef Pistoia W, van Rietbergen B, Lochmuller EM, Lill CA, Eckstein F, Ruegsegger P. Image-based micro-finite-element modeling for improved distal radius strength diagnosis: moving from bench to bedside. J Clin Densitom Off J Int Soc Clin Densitom. 2004;7(2):153–60.CrossRef
27.
go back to reference Macneil JA, Boyd SK. Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone. 2008;42(6):1203–13.CrossRefPubMed Macneil JA, Boyd SK. Bone strength at the distal radius can be estimated from high-resolution peripheral quantitative computed tomography and the finite element method. Bone. 2008;42(6):1203–13.CrossRefPubMed
28.
go back to reference Pialat JB, Burghardt AJ, Sode M, Link TM, Majumdar S. Visual grading of motion induced image degradation in high resolution peripheral computed tomography: impact of image quality on measures of bone density and micro-architecture. Bone. 2012;50(1):111–8.CrossRefPubMed Pialat JB, Burghardt AJ, Sode M, Link TM, Majumdar S. Visual grading of motion induced image degradation in high resolution peripheral computed tomography: impact of image quality on measures of bone density and micro-architecture. Bone. 2012;50(1):111–8.CrossRefPubMed
29.
go back to reference Hansen S, Hauge EM, Beck Jensen JE, Brixen K. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28(4):736–45.CrossRef Hansen S, Hauge EM, Beck Jensen JE, Brixen K. Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28(4):736–45.CrossRef
30.
go back to reference Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, Horslev-Petersen K, et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone. 1996;19(2):157–63.CrossRefPubMed Orum O, Hansen M, Jensen CH, Sorensen HA, Jensen LB, Horslev-Petersen K, et al. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone. 1996;19(2):157–63.CrossRefPubMed
31.
go back to reference Seung H, Medige J, Ziv I. Combined models of ultrasound velocity and attenuation for predicting trabecular bone strength and mineral density. Clin Biomech. 1996;11(6):348–53.CrossRef Seung H, Medige J, Ziv I. Combined models of ultrasound velocity and attenuation for predicting trabecular bone strength and mineral density. Clin Biomech. 1996;11(6):348–53.CrossRef
32.
go back to reference Merry GM, Aronowitz PB. Myelofibrosis with massive hepatosplenomegaly and osteolytic bone lesions. J Hosp Med Off Publ Soc Hosp Med. 2010;5(3):E27–8.CrossRef Merry GM, Aronowitz PB. Myelofibrosis with massive hepatosplenomegaly and osteolytic bone lesions. J Hosp Med Off Publ Soc Hosp Med. 2010;5(3):E27–8.CrossRef
33.
go back to reference Assous N, Foltz V, Fautrel B, Rozenberg S, Etchepare F, Bourgeois P. Bone involvement in myelofibrosis: effectiveness of bisphosphonates. Joint Bone Spine Revue du Rhumatisme. 2005;72(6):591–2.CrossRef Assous N, Foltz V, Fautrel B, Rozenberg S, Etchepare F, Bourgeois P. Bone involvement in myelofibrosis: effectiveness of bisphosphonates. Joint Bone Spine Revue du Rhumatisme. 2005;72(6):591–2.CrossRef
34.
go back to reference Blake GM, Fogelman I. An update on dual-energy X-ray absorptiometry. Semin Nucl Med. 2010;40(1):62–73.CrossRefPubMed Blake GM, Fogelman I. An update on dual-energy X-ray absorptiometry. Semin Nucl Med. 2010;40(1):62–73.CrossRefPubMed
35.
go back to reference Gregson CL, Steel SA, O’Rourke KP, Allan K, Ayuk J, Bhalla A, et al. Sink or swim: an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporos Int. 2012;23(2):643–54 (A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA).PubMedCentralCrossRefPubMed Gregson CL, Steel SA, O’Rourke KP, Allan K, Ayuk J, Bhalla A, et al. Sink or swim: an evaluation of the clinical characteristics of individuals with high bone mass. Osteoporos Int. 2012;23(2):643–54 (A Journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA).PubMedCentralCrossRefPubMed
36.
go back to reference Gregson CL, Hardcastle SA, Cooper C, Tobias JH. Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology. 2013;52(6):968–85.PubMedCentralCrossRefPubMed Gregson CL, Hardcastle SA, Cooper C, Tobias JH. Friend or foe: high bone mineral density on routine bone density scanning, a review of causes and management. Rheumatology. 2013;52(6):968–85.PubMedCentralCrossRefPubMed
37.
go back to reference Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine Revue du Rhumatisme. 2008;75(2):116–24.CrossRef Guggenbuhl P, Grosbois B, Chales G. Gaucher disease. Joint Bone Spine Revue du Rhumatisme. 2008;75(2):116–24.CrossRef
38.
go back to reference Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone. 2011;49(4):880–5.CrossRefPubMed Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone. 2011;49(4):880–5.CrossRefPubMed
39.
go back to reference Johansson C, Roupe G, Lindstedt G, Mellstrom D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing. 1996;25(1):1–7.CrossRefPubMed Johansson C, Roupe G, Lindstedt G, Mellstrom D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing. 1996;25(1):1–7.CrossRefPubMed
40.
go back to reference Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Annals Rheum Dis. 2010;69(10):1838–41.CrossRef Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Annals Rheum Dis. 2010;69(10):1838–41.CrossRef
41.
go back to reference van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy. 2012;67(3):431–8.CrossRefPubMed van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy. 2012;67(3):431–8.CrossRefPubMed
42.
go back to reference Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128(4):344–50.CrossRefPubMed Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol. 2002;128(4):344–50.CrossRefPubMed
43.
go back to reference Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer. Blood. 2012;119(14):3219–25.CrossRefPubMed Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer. Blood. 2012;119(14):3219–25.CrossRefPubMed
44.
go back to reference Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709–15.CrossRefPubMed Panteli KE, Hatzimichael EC, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709–15.CrossRefPubMed
45.
go back to reference Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(4):362–71.CrossRefPubMed Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol. 2011;86(4):362–71.CrossRefPubMed
46.
go back to reference Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med CCLM/FESCC. 2011;49(8):1271–4. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International osteoporosis foundation and international federation of clinical chemistry and laboratory medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med CCLM/FESCC. 2011;49(8):1271–4.
47.
go back to reference Barosi G, Costa A, Liberato LN, Polino G, Spriano P, Magrini U. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol. 1989;72(1):16–20.CrossRefPubMed Barosi G, Costa A, Liberato LN, Polino G, Spriano P, Magrini U. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol. 1989;72(1):16–20.CrossRefPubMed
48.
go back to reference Jensen MK, Riisbro R, Holten-Andersen MN, Brown Pde N, Junker P, Brunner N, et al. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur J Haematol. 2003;71(4):276–82.CrossRefPubMed Jensen MK, Riisbro R, Holten-Andersen MN, Brown Pde N, Junker P, Brunner N, et al. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur J Haematol. 2003;71(4):276–82.CrossRefPubMed
49.
go back to reference Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–62.CrossRefPubMed Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol. 2007;139(3):351–62.CrossRefPubMed
50.
go back to reference Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27(10):1953–8.CrossRefPubMed Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27(10):1953–8.CrossRefPubMed
51.
go back to reference Liu XS, Cohen A, Shane E, Yin PT, Stein EM, Rogers H, et al. Bone density, geometry, microstructure, and stiffness: relationships between peripheral and central skeletal sites assessed by DXA, HR-pQCT, and cQCT in premenopausal women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(10):2229–38.CrossRef Liu XS, Cohen A, Shane E, Yin PT, Stein EM, Rogers H, et al. Bone density, geometry, microstructure, and stiffness: relationships between peripheral and central skeletal sites assessed by DXA, HR-pQCT, and cQCT in premenopausal women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(10):2229–38.CrossRef
52.
go back to reference Boutroy S, Van Rietbergen B, Sornay-Rendu E, Munoz F, Bouxsein ML, Delmas PD. Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2008;23(3):392–9.CrossRef Boutroy S, Van Rietbergen B, Sornay-Rendu E, Munoz F, Bouxsein ML, Delmas PD. Finite element analysis based on in vivo HR-pQCT images of the distal radius is associated with wrist fracture in postmenopausal women. J Bone Miner Res Off J Am Soc Bone Miner Res. 2008;23(3):392–9.CrossRef
53.
go back to reference Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelfibrosis (Mf), essential thrombocythemia (Et), and polycythemia vera (Pv) in the european union (Eu). Eur J Haematol. 2013. Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelfibrosis (Mf), essential thrombocythemia (Et), and polycythemia vera (Pv) in the european union (Eu). Eur J Haematol. 2013.
54.
go back to reference Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leukemia Lymphoma. 2013. Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leukemia Lymphoma. 2013.
55.
go back to reference Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2981–7.CrossRef Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):2981–7.CrossRef
Metadata
Title
Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers
Authors
Sarah Farmer
Hanne Vestergaard
Stinus Hansen
Vikram Vinod Shanbhoque
Claudia Irene Stahlberg
Anne Pernille Hermann
Henrik Frederiksen
Publication date
01-07-2015
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2015
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1803-3

Other articles of this Issue 1/2015

International Journal of Hematology 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine